All News
Low Back Pain? Take a Walk!
A randomised controlled trial of adults with recurrent low back pain (LBP) has shown that a program of progressive walking and education intervention significantly reduced low back pain recurrence.
Read Article
The path to new technologies in rheumatology must be beset with caution
As we have incorporated technology into our workflows, and consequently saved lives and suffering, we have balanced our excitement about progress with proof that incremental advances can truly deliver benefit. it is easy to let promise carry our caution away - and while most of the time such advances come in a vetted package, which we can consume without concern, conference abstracts come raw. This is the necessary ingredient to a platform which allows for bold ideas and innovation, but for that reason it is not such a curated space. At EULAR 2024, we saw the usual mix of bright, raw ideas on the poster floor emblematic of this paradigm.
Read Article
Planetary Health in Rheumatology
Dr. Antoni Chan interviews Dr. Nelly Ziade about her session Planetary Health, presented at Eular 2024 in Vienna, Austria.
https://t.co/gBkwyO1dWQ https://t.co/VvGqwi6tlJ
Dr. John Cush RheumNow ( View Tweet)
Top 10 Drug companies (revenue)
10 Regeneron $12.2b
9 Vertex $8.9b
8 Amgen $26.3b
7 Gilead $27.3b
6 Lilly $28.5b
5 BMS $46.2b
4 Merck $59.3b
3 AbbVie $58.1b
2 J&J $94.9b
1 Pfizer $100.3b https://t.co/GNlGToGcb1 https://t.co/OWyVUBzeO6
Dr. John Cush RheumNow ( View Tweet)
JAMA: 3 prospective cohort studies in USA show that multivitamin use by 390 124 healthy adults did not alter mortality risk (HR, 1.04; 95% CI, 1.02-1.07) https://t.co/VDxrI5Bskw https://t.co/o9wdITR0UT
Dr. John Cush RheumNow ( View Tweet)
Artificial Intelligence: Detection of CPPD on Hand Radiographs
Dr. Antoni Chan interviews Dr. Thomas Hugle about abstract OP0112 presented at Eular 2024 in Vienna, Austria. https://t.co/jQrwKXuaDc https://t.co/Ecv69wvHxA
Dr. John Cush RheumNow ( View Tweet)
EUSTAr study of 4431 systemic sclerosis (SSc) pts - anti-SSA antibodies are detected in 15% of SSc-patients and represent an independent risk factor for the presence of lung fibrosis (OR 1.24) & more severe lung involvement. #EULA2024 OP0013 https://t.co/oW6NBjIG7E https://t.co/toyvHxJlr9
Dr. John Cush RheumNow ( View Tweet)
Cognitive Function in Older Adults: Worse in Lupus
Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria.
https://t.co/zedGdNbHw4 https://t.co/DIHvkEZRVk
Dr. John Cush RheumNow ( View Tweet)
The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria.
https://t.co/PXdHTWqVsX https://t.co/VZbZBk3a9f
Dr. John Cush RheumNow ( View Tweet)
The path to new technologies in rheumatology must be beset with caution
https://t.co/rostCE3UFT https://t.co/bn352RmrN8
Dr. John Cush RheumNow ( View Tweet)
Update on Sjogren's disease trials
With better endpoint and patient selection strategy over the last 4 years, many new therapies have met their endpoints/shown promising signal in the Phase 2 RCTs in Sjogren's disease.
https://t.co/qMxEX73BsM https://t.co/CQWaAIO4IK
Dr. John Cush RheumNow ( View Tweet)
New Treatments for Systemic Sclerosis
aHSCT for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed.
https://t.co/xUI0plrk42 https://t.co/DqGUhU6D1Z
Dr. John Cush RheumNow ( View Tweet)
ComOA- a cohort study from 3.4 million, 4 countries looked at OA (n=845K) & comorbidities. Tops were LBP (44%), HTN, (34%), allergy (21%), cataract (16%), vertigo (14%), depression (13%), DM (13%). After OA Dx: Fm, RA, PMR OP0230 #EULAR2024 https://t.co/GMVCHSfyt0 https://t.co/KFlacpHfAX
Dr. John Cush RheumNow ( View Tweet)
Does Telemonitoring in SpA Work?
Dr. Antoni Chan reports on abstract OP0120 from Eular 2024 in Vienna, Austria.
https://t.co/UUmnsAdx0t https://t.co/NE36OtKBwK
Dr. John Cush RheumNow ( View Tweet)
EULAR 2024 - Day 1 Report
https://t.co/LpYxUP8d7e https://t.co/5zwc0HsZZ8
Dr. John Cush RheumNow ( View Tweet)
Planetary health session #EULAR2024
Need to consider these in managing patients.
We in healthcare are contributing to emissions significantly!
@RheumNow https://t.co/Gxyrm5drCE
Links:
Bella Mehta bella_mehta ( View Tweet)
placebo effects can be huge!
#EULAR2024 @RheumNow https://t.co/RmcBAPG2Ye
Links:
Bella Mehta bella_mehta ( View Tweet)
CAR-T - autologous vs allogenic , need for full induction , safety of retreatment, CAR-T lymphoma/leukaemia, cost, ideal candidate ? @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
#IgG4 Pearls
Thanks for sharing
Isolated ⬆️ serum #IgG4 level
✅ How high? 5x ULN ➡️ PPV 75%
✅Typical organ(s) involved?
❓Another explanation
Dr Jone Stone
#Rheumatology #EULAR2024 https://t.co/UVKmH57iVM https://t.co/uxHBl0I3cM
Links:
Ask The Rheumatologist LastManStand85 ( View Tweet)
Mapping the knee #osteoarthritis joint-nerve interactome — presented by @AM_Malf at #EULAR2024. Anatomical and molecular neuroplasticity occurs during OA onset + progression in the joint and DRG. Cool imaging of nerves and their activity with lightsheet microscopy in mice https://t.co/cre6LEVhle
Tuhina Neogi, MD, PhD Tuhina_Neogi ( View Tweet)
